BERLIN, Feb 12 (Reuters) - The following are some of the factors that may move German stocks on Tuesday:
Bayer and Orion’s prostate cancer drug Darolutamide showed median metastasis-free survival (mfs) of 40.4 months vs 18.4 months with placebo in a phase III trial, according to a medical website.
Separately, Bayer’s Monsanto unit has won proceedings against Indian seed maker Nuziveedu Seeds Ltd (NSL) in a royalty dispute, lawyers familiar with the matter told Reuters.
Paul Achleitner, chairman of Deutsche Bank’s supervisory board, is scheduled to speak on “Europe and the Banking Challenge” at an event in Frankfurt.
ThyssenKrupp is expected to report a weak first quarter of its financial year, with investors eager for more granular details on a planned spin-off of its capital goods business, which has so far failed to revive its shares.
Fiscal Q1 results due.
Full year preliminary results due.
Tour operator TUI holds its annual general meeting. The company slashed its earnings guidance for its fiscal full year as last summer’s hot weather put holiday makers off booking trips and as the weak pound weighed on the purchasing power of its British customers.
TUI AG - 0.72 eur/shr dividend proposed
GEA Group - RBC cuts to “sector perform” from “outperform”
Dow Jones -0.2 pct, S&P 500 +0.1 pct, Nasdaq +0.1 pct at close.
Nikkei +2.6 pct, Shanghai stocks +0.6 pct.
Time: 5:38 GMT.
No economic data scheduled.
REUTERS TOP NEWS (Reporting by Berlin Speed Desk)